116 results about "Aging cell" patented technology

Described herein are methods and compositions for use in treating, preventing or reversing aging or age-related diseases, disorders or conditions. Also, described herein are methods and compositions for selective killing of senescent cells that are associated with numerous pathologies and diseases, including age-related pathologies, diseases and conditions. As disclosed herein are methods where senescent cell associated diseases and disorders may be treated or prevented (i.e., likelihood of occurrence or development is reduced) by administering the described compositions.

The invention provides a probe for cell senescence analysis and a preparation method and application thereof, and belongs to the technical field of cell detection. The invention discloses a probe for cell aging analysis. The probe comprises fusion protein formed by fibronectin RGD and fluorescent protein, the fibronectin RGD is a polypeptide fragment containing an amino acid sequence as shown in SEQ ID NO: 1. The probe is fixed on a solid-phase carrier and then co-incubated with cells to be detected, the condition of senescent cells can be analyzed and judged by detecting the intensity of a fluorescence signal, the purpose of rapid analysis is achieved, the analyzed cells can be recycled and then continuously cultured, the detection cost is low, and the probe is suitable for large-scale popularization and application in the market.

The present invention belongs to the technical field of gene therapy. Provided are a chimeric antigen receptor nanocomposite and a preparation method therefor and the use thereof in the preparation of an anti-aging drug. The provided chimeric antigen receptor nanocomposite comprises a chimeric antigen receptor DNA plasmid specifically recognizing senescent cells, a polymer coupled with a signal peptide, a free polymer and an antibody polymer targeting T cells, wherein the chimeric antigen receptor DNA plasmid, the polymer coupled with a signal peptide, the free polymer and the antibody polymer targeting T cells are sequentially mixed and incubated to form the chimeric antigen receptor nanocomposite. The chimeric antigen receptor nanocomposite can rapidly generate senescent cell-marked chimeric antigen T cells in vivo. The engineered T cells have the ability to specifically eliminate senescent cells in vivo, and can rapidly and durably eliminate senescent cells in vivo, which is irreplaceable and has wide application prospects.

The invention discloses a composition for reversing skin cell aging and application thereof, and relates to the technical field of cosmetics. The invention provides a composition. The composition comprises a component A and a component B, the component A comprises a camellia nitidissima extract, a camellia yunnanensis flower extract and a catechu extract; and the component B is oat beta-glucan. When the camellia nitidissima extract, the camellia yunnanensis flower extract and the catechu extract cooperate with the oat beta-glucan, small-molecule terpenoids and the like in the extracts can be used as natural penetration enhancers to form molecular channels with the oat beta-glucan; meanwhile, the components are synergistic, so that the removal of senescent cells can be enhanced, the cell regeneration is further enhanced, the cutin is effectively removed, the skin is brightened, and the mild anti-aging and brightening effects on the sensitive skin are achieved.

The invention relates to a repairing composition for reducing senescence cell cumulant and a preparation method and application thereof, and the repairing composition comprises the following components in parts by weight: 0.01-7.0 parts of probiotic pellets PDRN, 0.01-3.0 parts of microspheroidized PDRN, 0.01-10.0 parts of a ginseng root extract, 0.01-10.0 parts of red ginseng fermented vesicles, a thickening agent, functional components and water. Under a formula system of a thickening agent and functional components, the probiotic pellets PDRN, the microspheroidized PDRN, the ginseng root extract and the red ginseng fermented vesicles are added, and all the components have a synergistic effect, so that the composition can penetrate into skin to achieve the effect of accurately repairing mitochondrial dysfunction, can directly remove senescent cells, reduces the senescent cell cumulant in a body in multiple ways, and has a good effect on repairing mitochondrial dysfunction. Therefore, the prepared skin care composition can effectively delay skin aging.

The invention discloses a ternary fusion polypeptide Col-TF-1 targeting senescence cells, a monoclonal antibody mAb SC-1 matched with the ternary fusion polypeptide Col-TF-1, an anti-aging composition containing the ternary fusion polypeptide Col-TF-1 and the monoclonal antibody mAb SC-1, and application of the ternary fusion polypeptide Col-TF-1 The fusion polypeptide is formed by connecting a targeting peptide for targeting a senescence cell surface uPAR receptor, a collagen active peptide for promoting collagen synthesis and an immunomodulatory peptide for activating NK cells in series through a flexible linker GGGGS, and the amino acid sequence is as shown in SEQ ID NO.1. The invention further discloses a preparation method of the fusion polypeptide. Through CDR region humanized reconstruction and pH sensitive histidine switch design, the affinity of the matched antibody mAb SC-1 is improved by 5 times in a subacid environment, and the ADCC effect is enhanced through fucose-deficient host cells. Experiments show that when the fusion polypeptide is combined with the antibody, the senescent cell clearance rate can reach 45.2%, the collagen density is increased by 83.5%, and the effect is obviously superior to that of a single drug. The composition provided by the invention can be applied to the fields of cosmetics, medical instruments, medicines and functional foods, and provides a new strategy for treatment of senescence-related diseases and development of anti-senescence products.

The present invention discloses a photosensitizer prodrug compound (structural formula (I)) that selectively clears senescent cells and is specifically activated by the aging-associated β-galactosidase, as well as its preparation method and application. Upon activation by β-galactosidase, the compound rapidly releases its active molecule, anchoring it to proteins with nucleophilic groups. This allows for precise detection and covalent anchoring of senescent cells, thereby achieving selective clearance of senescent cells, reversing senescence-related markers and gene expression, and ameliorating aging-related decline in bodily functions. #imgabs0#

This invention discloses a fusion protein targeting the urokinase-type plasminogen activator receptor and its application in the field of anti-aging. The fusion protein is composed of a hepatocyte growth factor active domain and a humanized anti-uPAR single-domain antibody linked by a flexible linker peptide, and its specific amino acid sequence is SEQ ID NO:3. This fusion protein can specifically bind to uPAR, which is highly expressed on the surface of senescent cells, with intramolar affinity, achieving targeted delivery of the hepatocyte growth factor active domain. In vitro experiments have demonstrated that this protein can significantly reverse the aging phenotype of human fibroblasts, effectively reduce aging-related β-galactosidase activity, p16INK4a protein expression, and interleukin-6 secretion, and promote cell proliferation. In a rapidly aging mouse model, this protein can systematically improve age-related physiological functional decline. The fusion protein of this invention achieves specific targeting and efficient treatment of senescent cells, providing a new solution for the development of anti-aging drugs.

The present invention relates to the use of GRP78 and peptides similar thereto or nucleic acids encoding the same. The peptides or nucleic acids according to the present invention can increase the expression of biomarkers having reduced expression in senescent cells, and thus can be used to restore the function of muscle tissue that has decreased in function due to aging, etc.

The invention belongs to the technical field of biological medicines, and particularly relates to lipid nanoparticles as well as a preparation method and application thereof. The invention discloses a lipid nanoparticle. The material of the lipid nanoparticle comprises phospholipid and cholesterol. According to the invention, a lipid nano-carrier delivery system entrapped with apoptotic protein Bax is prepared through a microfluidic technology, and high encapsulation rate and stable delivery of protein drugs are realized. The nano-carrier delivery system capable of actively encapsulating the lipidosome realizes targeted delivery to senescent cells in vivo, so that senescent cell apoptosis is effectively induced, the proportion of senescent cells in tissues is reduced, and a new thought and means are provided for anti-aging treatment.

The application belongs to the technical field of functional polypeptides, and particularly relates to an active peptide for senescent cells and a preparation method thereof, wherein the active peptide is obtained by molecular docking simulation screening and optimization with a helical structure segment in an IL-6R protein combined with a gp130 protein as a polypeptide template; the active peptide after functional optimization contains an FF unit driving nano self-assembly, a GFLG unit capable of being specifically cut by a lysosome protease highly expressed in a microenvironment of senescent cells, and an RYFQKWEKLRNQ unit generating high affinity with an IL-6 / IL-6R / gp130 complex; the designed active peptide itself has anti-aging activity and can also be used for synergistic delivery of drugs, and has a broad application prospect.

The application belongs to the technical field of biological medicine, and particularly relates to an anti-aging ergothioneine composition for improving mitochondrial function and a preparation method thereof. The composition comprises the following components: ergothioneine, sea hao polysaccharide and entada extract. The ergothioneine has good mitochondrial targeted antioxidant activity, can up-regulate the expression of Sirt1 to activate PGC-1a, and promote mitochondrial biosynthesis; the sea hao polysaccharide is helpful to restore mitochondrial function, promote the generation of mitochondrial high-energy phosphoric compounds, improve cell activity and energy supply for regeneration, and can up-regulate the expression of key genes for mitochondrial biosynthesis and ATP synthase related genes. The entada extract can synergize with the ergothioneine and the sea hao polysaccharide, significantly down-regulate the expression of aging related proteins such as p53, p21 and p16 in cells, simultaneously inhibit the transcription of aging related genes, and has a good protective effect on aging cells.

The technology relates in part to compositions containing a cell penetrating peptide that can be used to selectively reduce a senescent cell population. The technology also relates to methods of treatment of ageing and ageing-associated diseases using a cell penetrating peptide to selectively reduce a senescent cell population.

The application discloses an engineered umbilical cord stem cell and application thereof in preparation of anti-aging drugs and medical beauty products. The application constructs an engineered cell system with high anti-aging function by designing a fusion polypeptide TAT-SIRT1-SOD (SEQ ID NO: 1) and an anti-p16INK4a monoclonal antibody (mAb-p16) to cooperatively modify the umbilical cord stem cell, and combining a 3D dynamic culture technology. The fusion polypeptide is mediated to cross the membrane by a TAT cell-penetrating peptide, activates SIRT1 and removes mitochondrial ROS; the mAb-p16 is specifically combined with p16INK4a on the surface of a senescent cell, and removes the senescent cell through an ADCC effect. Experiments show that the engineered umbilical cord stem cell can increase the removal rate of the senescent cell by 86.1%, increase the SOD activity by 300%, significantly inhibit the secretion of an inflammatory factor IL-6, and increase the skin collagen density by 148% and reduce the wrinkle depth by 67% in an animal model. The application provides a novel and efficient technical scheme for anti-aging drugs and medical beauty products.

The invention provides a linear or cyclic polypeptide and a derivative or analogue thereof, wherein the linear or cyclic polypeptide is used for mobilizing a stress-inducing protein (sestrin) from GATOR / mTOR to sMAC in a non-aging cell; the polypeptide comprises or consists of an amino acid sequence derived from a stress-inducing protein or a truncated sequence thereof. These polypeptides are useful in the treatment of conditions requiring immediate intervention, such as acute diseases, sepsis caused by pathogen infection, or anaphylaxis, such as allergic shock, as immunotherapeutic agents for the treatment of cancer, and for autoimmune diseases.

Senescent cells are implicated in aspects of age-related decline in health and may contribute to certain diseases. Embodiments include formulations and methods for promoting longevity and treating a senescence associated disease or disorder. Applicants present three distinct classes and multiple associated therapeutic molecules that can function alone or in combination with the other molecules. The classes include transcription regulators, lipid intermediates and microRNAs. Additional embodiments include methods of promoting longevity by administering GRAS substances.

Provided is the use of NKG2D-CD3 and NKG2D-CD16 cell adapter molecules in the removal of aging cells and the treatment of aging-cell-accumulation-related diseases, wherein the cell adapter molecules comprise an NKG2D extracellular domain, a connection segment, and a CD3 or CD16 binding domain. The death of aging cells having high expression of NKG2D ligand is efficiently induced by means of bridging aging cells and immune cells, and thus the cell adapter molecules of the present application can be used for removing aging cells expressing the NKG2D ligand and treating aging-related diseases.

The invention discloses a targeted multi-channel synergistic anti-aging composition as well as a preparation method and application thereof, and belongs to the technical field of functional foods and biological medicines. According to the composition disclosed by the invention, ginsenoside, a hawthorn polyphenol-chitosan phospholipid complex and spina date seed total saponins are taken as core active ingredients, and a specific Senlytics active ingredient and a natural mTOR inhibitor are compounded, so that the synergistic regulation of five anti-aging pathways, namely Sirtuins activation, mTOR inhibition, mitochondrial autophagy activation, CD38 inhibition and senescent cell removal, can be realized at the same time. The composition is natural in raw material source, high in safety and good in stability, can be prepared into various dosage forms such as capsules, solid beverages and oral liquid, is suitable for daily anti-aging and sub-health conditioning, and has wide application prospects in the fields of anti-aging health foods and biological medicines.

Materials and methods for regenerating senescent cells are provided. Aging cells are transduced with viral vectors to express Oct4, Sox2 and Klf4 proteins for partial cell reprogramming and to express dominant negative NF [kappa] BIA proteins to inhibit secretion phenotypes associated with aging. The materials and methods provided may be used to treat signs and symptoms of premature senility syndrome, premature aging, or natural aging, or to regenerate tissue in a subject experiencing premature aging or having an age-related disease.

Compositions of matter, devices, and treatment protocols for reducing deleterious effects of senescent cells in a mammal. The invention provides extracorporeal devices capable of removing, in some cases selectively, senescence associated factors including small molecules, proteins, lipoproteins, as well as in some embodiments extracellular vesicles including exosomes, apoptotic bodies, or cellular released particles. Extracorporeal removal of senescent cell associated factors is performed to augment effects of senolytic therapy. Removal of senescence associated factors is performed to enhance efficacy of regenerative medicine interventions.

This invention discloses a mitochondrial-targeted nanomaterial for senescent cells and its application in anti-aging. The material is a nucleic acid aptamer-tetrahedral DNA, mainly assembled from four single-stranded DNA sequences, SEQ ID Nos. 1-4. Preparation involves first hybridizing the four single-stranded DNA sequences, then concentrating them to obtain aptamer-modified tetrahedra, which are then coupled with tannic acid (TA) via a Mann reaction in the presence of formaldehyde to obtain the Apt-tFNAs-TA complex. Finally, it is incubated with excess catechins to obtain the final delivery material, Apt-tFNAs@catechin-TA. This invention's material exhibits good biocompatibility and skin tissue compatibility, significantly improving uptake efficiency and mitochondrial localization ability in senescent cells. It can effectively deliver polyphenolic compounds such as catechins and protocatechuic acid, improving mitochondrial function and addressing the technical problems of low delivery efficiency of active ingredients and insufficient targeted enrichment in senescent cells.

Disclosed herein are macrolide compounds having senescent cell elimination activity. These compounds selectively target senescent cells and can be used to reduce or eradicate senescent cells in a subject's body and / or delay the onset of aging. These compounds also inhibit the proliferation of cancer stem cells and can be used to treat cancer, particularly to inhibit the proliferation of cancer stem cells that cause metastasis and tumor recurrence.

The present invention provides methods for treating aging-related diseases or conditions in a subject in need thereof, killing or reducing the number of senescent cells in a subject in need thereof, improving the texture and / or appearance of the skin and / or hair of a subject in need thereof, and contributing to the treatment of obesity in a subject in need thereof, the methods comprising administering a therapeutically effective amount of one or more natural killer (NK) cell activators and / or a therapeutically effective number of activated NK cells to the subject.

This invention discloses *Bifidobacterium longum* with anti-aging functions and its applications, belonging to the field of microbial technology. The *Bifidobacterium longum* BBS 02 provided by this invention can promote cell vitality and proliferation, inhibit the high activity of β-galactosidase in senescent cells, and inhibit the high expression of the cyclin-dependent kinase inhibitor gene Cdkn1a, thereby achieving an anti-aging effect. The *Bifidobacterium longum* BBS 02 can be used to prepare edible nutrients or skin nutrients.

This invention proposes a nucleic acid aptamer that specifically binds to human senescent dermal fibroblasts (HDFs), along with its screening, identification, and application. Specific aptamers exhibiting high targeting specificity to human senescent HDFs were screened using Cell-SELEX technology. The three selected candidate aptamers showed binding rates of 57.5%, 86.2%, and 50.7% to senescent HDF cells within the same timeframe, respectively, demonstrating high specificity and targeted binding ability. Furthermore, the aptamer possesses potential for detecting, imaging, and regulating the function of senescent cells, successfully providing a new direction for targeted anti-aging interventions and therapeutic applications.

The present application belongs to the technical field of stem cell exosome preparation. More specifically, it relates to adipose-derived stem cells (ADSCs), conditioned medium (CM) thereof, and preparation method and use thereof in cosmetics and drugs. The present application provides a mesenchymal stem cell exosome preparation for delaying aging, wherein the exosome preparation is a conditioned medium obtained by culturing mesenchymal stem cells in a low-osmotic induction combined with epi-pen stimulation environment. Tests show that the conditioned medium can significantly enhance the proliferation and migration ability of senescent HSFs cells, reduce the expression of cell beta-galactosidase, reduce the expression of cell-related aging genes p16 and p53, and reduce the generation of intracellular ROS, and has a significant anti-aging effect.

The invention discloses a p16-OSKM transgenic mouse model and a reprogramming senescence cell construction method and application, and belongs to the technical field of cell biology and regenerative medicine. According to the method, a p16-OSKM hybrid mouse capable of specifically inducing an OSKM factor in a p16 high expression cell is obtained on the basis of hybridization of a p16-Ink4a-CreERT2 transgenic mouse, a Rosa26-CAG-LSL-rtTA3-IRES-mKate2 transgenic mouse and a Col1a1-TRE-OSKM-IRES-mCherry transgenic mouse. The selective activation of the OSKM factor in senescent cells with high expression of p16 can be realized by adding doxycycline into primary embryo fibroblasts separated from the mouse under an in-vitro culture condition, so that the senescent cells enter a cell cycle again and recover division and multiplication capacities. The technology provides an accurate model platform for basic research, and can be used for aging mechanism exploration, cell fate regulation and control, chronic disease treatment, development and screening of anti-aging drugs and the like.

The application discloses an engineered exosome targeting human urokinase-type plasminogen activator receptor uPAR and a preparation method and application thereof. Firstly, a high-affinity anti-human uPAR single-domain antibody VHH is prepared; then, a human umbilical cord mesenchymal stem cell engineering cell line expressing a VHH-PTGFRN fusion protein is constructed, and the engineered exosome is prepared and purified by combining three-dimensional hypoxic culture, chemical induction and size-exclusion chromatography technology. The engineered exosome comprises four comparative samples, wherein the core sample Exo^(VHH / miR) can simultaneously display the anti-uPAR VHH on the membrane surface to realize targeted delivery and enrich miR-193b-3p in the chamber to realize gene silencing, and the synergistic effect of the two can efficiently remove the uPAR high-expression senescent cells and inhibit the senescence-associated secretory phenotype SASP. The engineered exosome has the advantages of standardized preparation process, high yield and high purity, strong targeting, excellent curative effect and good safety, and can be used for preparing a treatment preparation for anti-aging and aging-related diseases, and has important clinical application value.

A system can be used to determine properties of a wellbore treatment fluid. The system can include a rotational system defining an axis of rotation and an aging cell. The aging cell can be positioned in the rotational system to rotate about the axis of rotation. The aging cell can include a housing, a sensor shaft, and a sensor. The housing can define an interior region of the aging cell to receive a wellbore treatment fluid. The sensor shaft can be at an angle from the axis of rotation and can be coupled to the interior region to transmit electronic signals about the wellbore treatment fluid. The sensor can be positioned on the sensor shaft to detect the electronic signals while the aging cell rotates about the axis of rotation, and the electronic signals can be used to determine the properties of the wellbore treatment fluid.

The invention discloses an application of loperamide in preparation of a medicine for treating osteoporosis, and belongs to the field of development of new application of medicines. Loperamide has the effects of inhibiting aging, increasing osteogenic differentiation of bone marrow mesenchymal stem cells and preventing osteoporosis of aged and postmenopausal mice; meanwhile, at the cellular level, loperamide can reduce expression of senescence factors in mouse mesenchymal stem cells, promote senescence cell apoptosis and inhibit cell senescence; and a new choice is provided for the treatment of senescence-related osteoporosis drugs.